Format

Send to:

Choose Destination
See comment in PubMed Commons below
Eur J Cancer. 2007 Mar;43(5):885-90. Epub 2007 Jan 24.

Response to melphalan in up-front investigational window therapy for patients with metastatic Ewing's family tumours.

Author information

  • 1Istituto Nazionale per lo Studio e la Cura dei Tumori di Milano, Milan, Italy. roberto.luksch@istitutotumori.mi.it

Abstract

The aim of the study was to determine the activity and toxicity of melphalan as a single agent given in up-front therapy for patients with newly-diagnosed Ewing's family tumours with bone/bone marrow metastases. Nineteen patients were enrolled from 2001 to 2004. The treatment consisted of up-front therapy with melphalan (two courses of 50 mg/m2, 3 weeks apart). The overall rate of response to melphalan (complete response+partial response, according to the RECIST criteria) was 78%. Transient grade 3-4 neutropenia, thrombocytopenia and anaemia were recorded in 97%, 81% and 28% of melphalan courses, respectively. No other relevant toxicities were recorded. Melphalan proved to be active in up-front treatment at non-myeloablative doses, and its toxicity was predictable and manageable. The schedule adopted did not interfere with any further intensive chemotherapy or myeloablative treatment in the majority of cases.

PMID:
17254770
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk